These findings provide a rationale for the combination of STAR0602 and SOC therapy in the clinical setting for patients with recurrent or metastatic HPV- HNSCC.

P1/2, N=50, Recruiting, Marengo Therapeutics, Inc. | Not yet recruiting --> Recruiting

P1/2, N=50, Not yet recruiting, Marengo Therapeutics, Inc.

These immunological and antitumor effects in mice were recapitulated in studies of STAR0602 in nonhuman primates and human ex vivo models, wherein STAR0602 boosted human antigen-specific T cell responses and killing of tumor organoids. Thus, STAR0602 represents a distinct class of T cell-activating molecules with the potential to deliver enhanced antitumor activity in checkpoint inhibitor-refractory settings.

To our knowledge, the use of therapeutic antibodies to selectively target and expand Vβ T cell subsets and thereby modulate the germline TCR repertoire for therapeutic benefit is novel. Here we show that STAR0602 selectively binds and activates human Vβ6/Vβ10 T cells and promotes a novel TCM phenotype. Murine surrogate molecules targeting different Vβ T cell subsets demonstrated potent and durable single-agent anti-tumor activity even when targeting low frequency Vβ subsets.

P1/2, N=365, Recruiting, Marengo Therapeutics, Inc. | Not yet recruiting --> Recruiting

P1/2, N=365, Not yet recruiting, Marengo Therapeutics, Inc.